TRYPTO Therapeutics GmbH

Trypto Therapeutics GmbH is a Berlin-based biotechnology research company that specializes in developing proprietary small molecule inhibitors to treat diseases associated with elevated peripheral serotonin levels. The company focuses on tryptophan hydroxylase (TPH) inhibitors, such as TPT-001 and TPT-004, which are designed with nanomolar potency to selectively target TPH1 in the periphery. By inhibiting this enzyme, the company aims to reduce pathologically high serotonin synthesis while avoiding the blood-brain barrier, providing a differentiated therapeutic approach compared to existing treatments.

The company was established as a spin-off from the Max Delbrück Center and the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) to advance these drug candidates toward clinical trials. Trypto Therapeutics primarily targets conditions such as pulmonary arterial hypertension (PAH), carcinoid syndrome, and other chronic inflammatory or fibrotic diseases driven by serotonin imbalance. By developing these therapeutics, the company seeks to address significant unmet medical needs in patients suffering from serotonin-dependent pathologies, transitioning academic discoveries into viable pharmaceutical candidates for human clinical application.